Maravai Lifesciences Holdings (MRVI) Payables (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Payables of $8.5 million for Q1 2026, down 10.39% year-over-year from $9.5 million in Q1 2025, and up 193.3% quarter-over-quarter from $2.9 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Payables (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Payables history runs 7 years deep, the most recent figure standing at $8.5 million for Q1 2026.
- In Q1 2026, Payables fell 10.39% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $8.5 million (down 10.39% YoY), while the FY2025 annual figure was $2.9 million, down 75.66% from the prior year.
- Payables for Q1 2026 stood at $8.5 million, up from $2.9 million in the prior quarter.
- The five-year high for Payables was $678.4 million in Q3 2023, with the low at $2.9 million in Q4 2025.
- The 5-year median for Payables is $10.0 million (2022), against an average of $94.7 million.
- The sharpest annual moves came in 2023 and 2024: Payables jumped 7072.01% in 2023, then slumped 98.12% in 2024.
- Maravai Lifesciences Holdings' Payables stood at $42.3 million in 2022, then sank by 83.27% to $7.1 million in 2023, then soared by 69.15% to $12.0 million in 2024, then sank by 75.66% to $2.9 million in 2025, then surged by 193.3% to $8.5 million in 2026.
- Business Quant data shows MRVI's Payables at $8.5 million in Q1 2026, $2.9 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 7.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.13 Mn |
| Mar 31, 2026 | 8.54 Mn |
| Dec 31, 2025 | 2.91 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Jun 30, 2025 | 11.53 Mn |
| Mar 31, 2025 | 9.53 Mn |
| Dec 31, 2024 | 11.96 Mn |
| Jun 30, 2024 | 12.54 Mn |
| Mar 31, 2024 | 7.10 Mn |
| Dec 31, 2023 | 7.07 Mn |
| Sep 30, 2023 | 678.40 Mn |
| Jun 30, 2023 | 667.93 Mn |
| Mar 31, 2023 | 4.78 Mn |
| Dec 31, 2022 | 42.25 Mn |
| Sep 30, 2022 | 9.46 Mn |
| Jun 30, 2022 | 23.27 Mn |
| Mar 31, 2022 | 10.38 Mn |
| Dec 31, 2021 | 8.15 Mn |
| Sep 30, 2021 | 8.92 Mn |
| Jun 30, 2021 | 11.70 Mn |